Dr. Andrew Lyon is the recipient of the Canadian Society of Clinical Chemists (CSCC) Award for Outstanding Contribution to Clinical Chemistry for 2026. This award for outstanding achievement in and/or contribution to the field of clinical chemistry recognizes the many achievements during Dr. Lyon’s career of over 35 years where he has demonstrated excellence as clinical biochemist, educator, leader, and scholar. He has left a positive and impactful mark on practically every aspect of the profession.

Known for his collegial approach, Dr. Lyon is described as a visionary clinical chemist who understands how to best serve patients and medical colleagues by fostering strong professional relationships. In leadership roles, Dr. Lyon has demonstrated exceptional administrative and strategic skills. He served as Division Head of Clinical Biochemistry at Calgary Laboratory Services from 2003 to 2008 followed by the same role in Saskatoon from 2012 to 2024. His ability to mentor and develop others has been critical to cultivate the next generation of clinical chemists and laboratory leaders.

His service to the profession has been extensive and sustained over the past decades. Dr. Lyon has been a Fellow of the Canadian Academy of Clinical Biochemistry (CACB) since 1994 and has held numerous leadership roles within the CACB, including Chair of the Certification Committee and member of the Board of Directors. He has also served the CSCC in multiple leadership and governance roles, including Councillor, Division Head of Educational Affairs, and most notably as CSCC President during 2015 to 2017. But what is little known among the most current members is that Dr. Lyon was instrumental in leading the very first iteration of the CSCC website.  The launch of the “www.cscc.ca” domain coincided with the 1997 CSCC annual meeting in Halifax.

Dr. Lyon has received numerous awards throughout his career including the CSCC Award for Research Excellence, Donald J. Campbell Award for Outstanding Contribution to Clinical Biochemistry from the Alberta Society of Clinical Chemists (ASCC), the CACB Outstanding Contribution to the Profession of Clinical Biochemistry, the Bayer Diagnostics Scholarship from the Clinical Laboratory Management Association (CLMA), and the AVL Scientific Award for Significant Advances in Critical Care Testing for Canada from the International Federation of Clinical Chemistry (IFCC).

Having held faculty positions in medical schools at the University of Saskatchewan and the University of Calgary, Dr. Lyon has made significant scholarly contributions, including 102 peer‑reviewed publications, more than 116 abstracts and conference proceedings, 7 book chapters, and numerous additional publications. His expertise is recognized nationally and internationally, evidenced by more than 30 invited talks. His research has been supported by major funding agencies such as Canadian Institutes of Health Research (CIHR) and the Alberta Heritage Foundation for Medical Research. He has also contributed widely to the scientific community through service on grant review panels and editorial boards for leading journals in clinical chemistry and laboratory medicine.

As an educator, Dr. Lyon has a vast depth of experience teaching undergraduate and graduate students, including the supervision or advisory of several master’s and PhD students. He is widely respected for his ability to explain complex biochemical and laboratory medicine concepts in a way that is accessible and meaningful to learners at all stages of training. His long-standing commitment to education is reflected not only in the classroom, but also through his extensive involvement in continuing medical education, conference planning activities, and professional societies.

The entire CSCC community recognizes the unwavering dedication of Dr. Lyon to the field of clinical chemistry and his tireless efforts to advance it. As colleagues, learners, and ultimately the patients and public, we have benefitted from Dr. Lyon’s leadership through significant and positive contributions to diverse areas through laboratory medicine.

1. The Award shall be presented as a mark of recognition of outstanding achievement in and/or contribution to the field of clinical chemistry.
2. The Award shall usually be presented annually, but if in the opinion of the Awards Committee no suitable candidate is available in any year, the Award shall not be made.
3. Siemens has agreed to make an annual contribution of $3,000 CDN to sponsor this award. A framed certificate and an honorarium in the amount of $1,500 shall accompany the Award. The balance of $1,500 remaining after the honorarium shall be used to meet the administrative expenses, the production of the framed scroll, and to make a contribution towards expenses involved in ensuring the attendance of the recipient at the Annual Conference of the Society.
4. The Awards Committee shall choose the recipient of the Award.
5. The Awards Committee shall report its choice to the Council of the Society at its Winter Meeting in the year for which the Award is made.
6. The President of the Society will notify the recipient(s) of the award and inform Siemens Inc. of the name of the recipient(s) of the Award not later than March 1, in the year for which the Award is made.  
7. The recipient of the Award is not usually expected to give an address or give a paper, but the Award and the reading of the citation shall usually be made at the Annual Conference of the Society. A representative of Siemens shall be invited to participate in the presentation.
8. No formal nomination procedure is specified, but members of the Society may propose suitable candidates to the Awards Committee through the Head Office of the Society. Curriculum vitae and other suitable documentation in support of the nominee must accompany nominations from the membership. Proposals shall be solicited annually in the Newsletter of the Society.
9. The amendment of these Terms of Reference is the responsibility of the Council, subject to the concurrence of the sponsor of the Award. Council of the Society and the corporate sponsor of this award should review these terms of reference a minimum of once every 5 years.

The CSCC Award for Innovation in Laboratory Medicine is presented to a clinical laboratory in Canada that has distinguished itself by outstanding accomplishment through innovation in the field of clinical chemistry, pathology, or laboratory medicine. The 2026 recipient is Alberta Precision Laboratories (APL). The Clinical Chemist team innovated with a provincial testing program for hemoglobinopathies.

All requests for hemoglobinopathy investigations across the entire province of Alberta (including confirmation of positive newborn screens) now follow a standardized testing algorithm that includes initial screening by capillary electrophoresis, complete blood count and iron studies, followed by reflexive confirmatory testing with gel electrophoresis and/or molecular analysis. Interpretation of results has also been standardized through the development of a comprehensive procedure and canned comments that cover >95% of cases. The endeavor started in 2022 with initial roll out by the Edmonton team in the spring of 2023. After a period of training and handover to the Calgary team, the provincial data analysis and optimization of reflex thresholds was completed in 2025, reducing unnecessary analyses and saving valuable healthcare resources.

The province wide hemoglobinopathy testing program collaborated with the Departments of Hematopathology and Genetics and Genomics, as well as Hematologists across Alberta, to design, implement, and optimize the process. The innovative program had 3 important goals:

1. Transition hemoglobinopathy screening from the Hematopathology Department to the Chemistry Department by advocating for Clinical Chemistry oversight, acquiring and validating new instrumentation, and leading staff training.
2. Develop and implement a provincial program for hemoglobinopathy testing that encompasses both initial screening and confirmatory analysis, developing a comprehensive interpretive algorithm, and standardized reports.
3. Optimize reflexive thresholds for confirmatory testing by completing in-depth data analysis, engaging clinical stakeholders, and implementing evidence-based practice changes.

The team of Clinical Chemists at APL took the initiative to understand existing practices, design an improved provincial algorithm, and prepare the business case to consolidate testing provincially under Chemistry. At the laboratory level, the team validated new instruments, created standardized interpretive procedures, and trained staff across the province. For clinical engagement, they worked collaboratively with key stakeholders to design a provincial algorithm based on clinical needs and best practices, and conducted education for healthcare providers. After rollout, they analyzed provincial data to refine confirmatory testing criteria and guided stakeholders through updates and implementation. In one example, the optimized screening for alpha-thalassemia eliminated 350 unnecessary molecular tests/year thus saving valuable healthcare resources.

Implementation of a standardized provincial hemoglobinopathy program has resulted in consistency of both testing and reporting, no matter where in the province a sample is drawn. Development of a single comprehensive interpretative procedure has enhanced efficiency, decreased errors, and facilitated teaching the next generation of healthcare professionals. It has also ensured equal access to confirmatory testing for all Albertans, including expedited confirmation of positive newborn screening results for hemoglobinopathies. A cross-disciplinary approach that leverages the expertise of Clinical Chemists, Hematopathologists, and Molecular Geneticists has fostered continuous learning and new collaborations.

The program exemplifies that Clinical Chemists can play a central role in large-scale hemoglobinopathy testing, a responsibility traditionally led by hematopathologists. By working across disciplines, Clinical Chemists demonstrate value by managing screening interpretation and program optimization, while Molecular Geneticists and Hematopathologists handle molecular confirmations and additional testing. This teamwork ensures accurate diagnoses for complex cases. As a result of their efforts, a standardized, province‑wide approach to hemoglobinopathy testing was achieved. The success of Alberta Precision Labs’ model may encourage other jurisdictions to involve Clinical Chemistry more fully and adopt similar integrated, standardized testing frameworks.

The team now signs out most hemoglobinopathy cases in the province, raising the profile of Clinical Chemistry within the healthcare system. Their expertise has led to frequent consultations from hematologists, genetic counselors, and other clinicians, strengthening interdisciplinary relationships. The initiative has also enhanced the Chemistry Department’s academic presence at both the University of Alberta and the University of Calgary, where the team’s expertise has positioned them to provide hemoglobinopathy education to medical residents and fellows across Alberta, earning them consistently excellent evaluations.

Congratulations to Dr. Mathew Estey (Medical Lead Clinical Biochemistry, Hub Lab North), Kay Ng (Director, Hub Lab North), and the entire APL Clinical Chemist team for the success of their development of a new laboratory program.

1. The Award shall be presented to a Clinical Laboratory in Canada that has distinguished itself by outstanding accomplishment through innovation in the field of Clinical Chemistry, or Pathology and Laboratory Medicine for projects where a CSCC member was directly involved. This award is intended to encourage and recognize excellence in Clinical Laboratory Services especially in the role of improving the quality of health care, improving patient outcomes, and promoting a positive public image to clinical laboratories and laboratory professionals.
2. Eligible organizations for this award include:
   1. Private, Academic and Government Clinical Laboratories and Laboratory divisions.
   2. Rural and Regional Clinical Laboratories and Clinical Laboratory Departments.
3. Laboratories demonstrating outstanding accomplishments in one or more of the following areas completed within the last two calendar years are eligible for consideration:
   1. Innovation in strategic planning and implementation of laboratory services based on best practices.
   2. Innovation in development of new laboratory programs (e.g. new tests, facilities, and changes in practice).
   3. Innovation in teaching and education.
   4. Promotion of a positive public image for laboratory medicine.
4. Nominations for this award will be received from members of the CSCC to the Awards Committee through the Head Office of the Society. Nominations for this award will include:
   1. A summary of the accomplishment(s) of the nominated organization with supporting documentation.
   2. A letter of support from a CSCC member involved in the project for which the organization is being nominated.
   3. A letter of support from the nominee’s organization administrative team (Signed by a Department Director, VP, or CEO).
5. Nominees having received this award within the last 3 years will not be eligible to receive this award for a current year.
6. Nominations for this award shall be solicited annually in the Newsletter of the Society.
7. The Award shall usually be presented annually, but if in the opinion of the Awards Committee there is no suitable candidate(s) available in any year, the Award shall not be made.
8. The Awards Committee shall select one of the nominees for the Award for recommendation to Council of the Society.
9. The Awards Committee shall report its recommendation to the Council of the Society for approval at its Winter Council meeting in the year for which the Award is to be made.
10. The President of the Society will notify the recipient organization of the Award and inform Roche Diagnostics of the name of the recipient of the award, not later than March 1 in the year in which the Award is made.
11. The CSCC supporting member and a representative from the administration of hospital or institution represented in the project will be invited to accept the award (display item) at the CSCC Annual Meeting. The award will be presented by a representative from Roche Diagnostics. The award will cover airfare, accommodation and expenses for 2 nights for both recipients, as per the CSCC Travel Guidelines. The intent is for CSCC to support the primary applicant to attend. If there are co-lead(s), then the primary applicant is to determine if/how funds will be shared. The expectation is that the CSCC would support the applicant in finding an administrator (clinical or operational) to receive the award.
12. The recipient of the Award is not usually expected to give an address, but the Award and the reading of the citation shall usually be made at the Annual Conference of the Society.
13. The amendment of these Terms of Reference is the responsibility of the Council, subject to the concurrence of the donor of the Award and should be reviewed at least every five years.

CSCC Award for Innovation in Laboratory Medicine – nomination form

Dr. Lei Fu is the recipient of the 2026 CSCC Award for Research Excellence. This award is presented to an individual or group for their contribution to research directly or indirectly related to clinical chemistry in Canada.

Dr. Fu has contributed significantly to the understanding of biomarkers in maternal-fetal health and clinical applications of pharmacogenetics. Her translational research work has enabled greater personalized medicine that has direct impact on the well-being of patients. Currently, she is clinical biochemist in the Precision Diagnostics and Therapeutics Program at Sunnybrook Health Sciences Centre and holds the position of Associate Professor in the Department of Laboratory Medicine and Pathobiology at the University of Toronto.

After her graduate studies, Dr. Fu completed postdoctoral research in pharmacology and molecular virology at the Yale University School of Medicine. This was followed by clinical chemistry training in the McMaster University fellowship program prior to joining Sunnybrook in 2002. In addition to her CACB certification, she is a Diplomate of the American Board of Clinical Chemistry in three disciplines: Clinical Chemistry, Toxicological Chemistry, and Molecular Diagnostics.

Dr. Fu has successfully secured funding from both local and international sources, facilitating her work in advancing applied medical research to enhance patient care. She has published and presented her work at provincial, national, and international levels, where several of her contributions have received outstanding research recognition from the Association for Diagnostics & Laboratory Medicine (ADLM). A notable achievement of Dr. Fu’s is her instrumental role in making Sunnybrook the first hospital in North America to implement innovative assays—soluble fms-like tyrosine kinase 1 (sFLT-1) and placental growth factor (PlGF)—for diagnosing preeclampsia in pregnant women. This advancement enables clinicians to provide more accurate diagnostics and was acknowledged through the 2024 CSCC Award for Innovation in Laboratory Medicine. Furthermore, Dr. Fu developed a multiplex AS-PCR assay to rapidly detect five variants in the DPYD gene, which is crucial for fluoropyrimidine metabolism. This assay can be used for screening DPYD variants to identify patients with increased risk of toxicity when prescribed fluoropyrimidine therapy.

In addition to her research achievements, Dr. Fu is dedicated to education, teaching both graduate and undergraduate courses. She has supervised over twenty research students, medical doctors, postdoctoral fellows, and medical laboratory technologists, fostering the next generation of professionals in the field.

Dr. Fu actively shares her expertise through many professional bodies at the international level including Clinical Pharmacogenetics Implementation Consortium (CPIC), Pharmacogene Variation Consortium (PharmVar), ADLM Academy, International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT), and Clinical and Laboratory Standards Institute (CLSI).  More importantly, she is able to bring her knowledge home for the benefit of Canadians, particularly in Ontario where she serves on provincial bodies advising on pharmacogenomic and pharmacogenetic testing and also preeclampsia screening in the first trimester.

1. The Award shall be presented to an individual or group, as a mark of recognition of their contribution to research directly or indirectly related to clinical chemistry in Canada.
2. The Award shall usually be presented annually, but if in the opinion of the Awards Committee no group or individual is available in any year, the Award shall not be made.
3. QuidelOrtho have agreed to make an annual contribution of $3,000 CDN. The Award shall be accompanied by a framed certificate and by an honorarium in the amount of $1,500. The balance of $1,500 remaining after the honorarium shall be used to meet the administrative expenses, the production of the framed scroll, and to make a contribution towards expenses involved in ensuring the attendance of the recipient at the Annual Conference of the Society.
4. The Awards Committee shall choose the recipient(s) of the Award.
5. The Awards Committee shall report its choice to the Council of the Society at its Winter Meeting for the year for which the Award is made.
6. The President of the Society will notify the recipient(s) of the award and inform Ortho Clinical Diagnostics of the name of the recipient(s) of the Award not later than March 1, in the year for which the Award is made.
7. The recipient(s) of the Award is (are) not usually expected to give an address or present a paper, but the Award and the reading of the citation shall usually be made at the Annual Conference of the Society.  A representative of QuidelOrtho shall be invited to participate in the presentation.
8. No formal nomination procedure is specified, but members of the Society may propose suitable candidates to the Awards Committee through the Head Office of the Society. Curriculum vitae and other suitable documentation in support of the nominee must accompany nominations from the membership. Proposals shall be solicited annually in the Newsletter of the Society.
9. The amendment of these Terms of Reference is the responsibility of the Council of the Society, subject to the concurrence of the sponsor of the Award.  Council of the Society and the corporate sponsor of the Award should review these Terms of Reference a minimum of once every five years.

Dr. Anna Füzéry is the recipient of the 2026 CSCC Award for Education Excellence. This award is presented to an individual or group as a mark of recognition of outstanding contribution to education in the field of clinical chemistry.

Dr. Füzéry is currently the North Sector Point of Care Testing Medical Lead at Alberta Precision Laboratories and also Associate Clinical Professor in the Department of Laboratory Medicine and Pathology, University of Alberta, where she serves as Co-Director of the Clinical Biochemistry Postdoctoral Fellowship Program.

After she completed her fellowship training at Johns Hopkins University, Dr. Füzéry joined Alberta Health Services / Alberta Precision Laboratories in 2013 as a clinical biochemist supporting tertiary care and suburban hospitals and specialized in point of care testing (POCT) within Edmonton and North zones. Since then, she also gained formal professional certification in POCT, and is a recognized leader in the development, implementation, and delivery of POCT programs.

As an educator and mentor, Dr. Füzéry has inspired and supported countless students, trainees, and peers. As a co-director of the Clinical Biochemistry Fellowship program since 2015, she has shaped the next generation of laboratory professionals with skill, patience, and dedication. She strengthened the program by tirelessly supporting trainees with tools to achieve excellence including for pathophysiology learning resources, supplemental exposures, and additional rotations to fine tune the curriculum based on their personal preference. Fellows and residents in General Pathology consistently describe her guidance as transformative, providing not only technical expertise but also the values of professionalism, integrity, and lifelong learning. At the undergraduate level, she supervised numerous students in the medical laboratory science program with their fourth-year research project

Through her dedicated service to the profession, Dr. Füzéry has made an immeasurable impact on continuing education and the advancement of knowledge in laboratory medicine. She has provided leadership at the provincial, national, and international levels, chairing and contributing to numerous committees. Notable examples include serving as Chair of the Association for Diagnostics & Laboratory Medicine (ADLM) Rocky Mountain Section, Co-Chair of the CSCC Annual Conference, Head of the Education and Scientific Division of the CSCC Council, member of the ADLM Annual Meeting Organizing Committee, member of the CPSA Advisory Committee, Corresponding Member for the IFCC Mobile Health and Bioengineering in Laboratory Medicine group, and member of the CLSI Expert Panel on Point-of-Care Testing.  Many of these activities have lasting educational impact throughout the CSCC and on the field of clinical chemistry.

1. The Award shall be presented to an individual or group as a mark of recognition of outstanding contribution to education in the field of clinical chemistry.
2. The Award shall usually be presented annually, but if in the opinion of the Awards Committee no suitable candidate is available in any year, the Award shall not be made.
3. Beckman Coulter Canada Inc. have committed to an annual contribution of $3,000 CDN. A framed certificate and an honorarium in the amount of $1,500 shall accompany the Award. The balance of $1,500 remaining after the honorarium shall be used to meet the administrative expenses, the production of the framed scroll and to make a contribution towards the expenses involved in ensuring the attendance of the recipient at the Annual Conference of the Society.
4. The Awards Committee shall choose the recipient(s) of the Award.
5. The Awards Committee shall report its choice to the Council of the Society at its Winter Meeting in the year for which the Award is made.
6. The President of the Society will notify the recipient(s) of the award and inform Beckman Coulter Canada Inc. of the name of the recipient(s) of the Award not later than March 1, in the year for which the Award is made.
7. The recipient(s) of the Award is (are) not usually expected to give an address or present a paper, but the Award and the reading of the citation shall usually be made at the Annual Conference of the Society.  Representatives of Beckman Coulter Canada Inc. shall be invited to participate in the presentation.
8. No formal nomination procedure is specified, but members of the Society may propose suitable candidates to the Awards Committee through the Head Office of the Society. Curriculum vitae and other suitable documentation in support of the nominee must accompany nominations from the membership. Proposals shall be solicited annually in the Newsletter of the Society.
9. The amendment of these Terms of Reference is the responsibility of the Council, subject to the concurrence of the sponsor of the Award.  The CSCC Council and the corporate sponsor of the Award should review these Terms of Reference a minimum of once every five years.

Terms of Reference

ELIGIBILITY REQUIREMENTS
1. Applicants must be members of the CSCC.
2. Applicants must be enrolled EITHER in a CACB-accredited clinical biochemistry training program OR in a Royal College of Physicians and Surgeons of Canada-accredited medical biochemistry training program.

ADDITIONAL REQUIREMENTS
1. The Host Laboratory must perform clinical service in biochemistry, hematology, microbiology, immunology, genetics, and/or a related area.
2. The Host Laboratory must be located outside of the home city of the Applicant’s training program.
3. Funds must be used within one year of being awarded or before completion of the training program, whichever is earlier.
4. Successful Applicants must submit a summary article of their visit to CSCC News before completion of their training program. The article should describe goals that were achieved during the visit and how Applicants plan to apply their new knowledge in the future. Applicants should coordinate the length and timing of their articles with the Editor in Chief of the publication.

APPLICATION PROCESS
The applicant is to submit an online application via the CSCC website. The application deadline is April 10, 2026.

AWARDING OF GRANTS
CSCC Head Office will forward all applications to the Head of CSCC Professional Affairs Division (PAD) who will then appoint up to three (3) reviewers per application. All reviewers are required to be CSCC members; one should be the Head of the Education and Scientific Affairs Division, and one should be a CSCC Councillor if there is no conflict of interest. In awarding the grants, preference will be given to applicants who will be in their final year of study during the proposed visit and/or have not previously received a CSCC Trainee Elective Visit Grant. Whenever possible, grants will be distributed across two or more training programs each year. The reviewers complete scoring sheets and submit them to Head Office (info@cscc.ca). Head Office will notify applicants of the reviewer panel’s decision within one (1) month of receiving applications.

Updated and approved by Council, June 30, 2025.

Application Form

Download PDF

Terms of Reference

1. The Grant shall be presented to a member of the CSCC to support leadership and/or administrative contributions in the field of Clinical Chemistry or Pathology and Laboratory Medicine. This award is intended to encourage and support the administrative and leadership role of Laboratory Physicians and Scientists including (but not limited to):
a) administrative positions in hospitals, universities, private laboratories, government and
industry,
b) participation in committees of Provincial, National and International professional and
regulatory agencies,
c) leadership role in the strategic planning and implementation of laboratory services.

2. The applicant is to submit an online application via the CSCC website for consideration by the Awards Committee. Applicants will have to submit with their application a statement explaining why this grant is required, and a proposed budget. If their employer provides funds for education and travel, the candidates shall explain why these funds cannot be used for the purpose requested.

3. The deadline for applications is November 30 each year. Preference is to award the grant for an activity occurring in the award year that has not yet occurred. Exceptions may be considered by the Awards Committee with approval by Council.

4. The Grant shall usually be presented annually, but if in the opinion of the Awards Committee no suitable candidate(s) is available in any year, the Grant shall not be made. A maximum of three grants shall be given in any fiscal year. If the grant has not been awarded, the grant may remain open for the remainder of the award year.

5. Recipients of the Grant shall receive a maximum of $3,000, sponsored by CSCC Council.

6. Awarding of this grant is subject to available funds from the CSCC. Grant monies may be reduced, or the grant may not be funded in any given year, at the discretion of the Council.

7. The Awards Committee shall choose the recipient of the Award.

8. The Awards Committee shall report its choice to the Council of the Society not later than January 15 in the year for which the Grant is made.

9. The President of the Society will notify the recipient(s) of the Grant not later than March 1 in the year in which the Grant is made.

10. The recipient of the Grant is not usually expected to give an address or present a paper, but the Grant and the reading of the citation shall usually be made at the Annual Conference of the Society.

11. Proposals shall be solicited annually in the Newsletter of the Society.

12. The amendment of these Terms of Reference is the responsibility of the Council and should be reviewed at least every five years.

CSCC Grant for Leadership Application Form

Download Trainee Grant TOR

Participation in the Annual Conference of the CSCC provides trainees in laboratory medicine with a valuable opportunity to increase their knowledge in laboratory medicine and related fields, to discuss their work with colleagues, and to establish novel collaborative relationships.

CSCC provides a limited number of Trainee Travel Grants each year in support of this important facet of laboratory medicine training. Trainees are encouraged to apply for these grants if they meet all the following criteria:

1. They are members of the CSCC.
2. They are enrolled EITHER in a CACB-accredited clinical biochemistry training program OR in a Royal College of Physicians and Surgeons of Canada-accredited medical biochemistry training program.
3. They are presenting work at the Annual Conference of the CSCC that they performed during their current traineeship.

In awarding the travel grants, the CSCC Awards Committee will consider the following additional criteria:

1. Preference will be given to trainees:

• In their final year of study
• Who have not previously received a CSCC Trainee Travel Grant, AND
• Who reside outside of the city where the conference is being held.

2. Abstracts will be evaluated based on the amount of work involved in the study and the applicability of the results to the practice of Clinical/Medical Biochemistry. Preference will be given to clinical and analytical abstracts, followed by basic research.
3. Whenever possible, grants will be distributed across two or more training programs.

Trainees must send ALL the following information to CSCC Head Office (info@cscc.ca) to be considered for this Grant:

1. Name and institution of their training program,
2. Current year of training,
3. A copy of their submitted abstract, AND
4. Proof of acceptance of the abstract for presentation (Submitted within two weeks of notification of acceptance of abstract(s) by the conference organizing committee). Applicants will be notified by Head Office as soon as possible after all received travel grant applications have been reviewed.

Updated and approved by CSCC Council, June 30, 2025.

CSCC Grant for Educational Activities

1. The Grant(s) shall be presented to a Full member of the CSCC to support their educational activities and/or development of the profession in the field of Clinical Chemistry or Pathology and Laboratory Medicine. The grant is intended to encourage and support members who require additional funding, beyond that provided by their employer, to attend national/international conferences, take additional courses, or participate in other educational activities and professional development including (but not limited to): a. Attendance at the CSCC annual meeting or another national or international meeting relevant to laboratory medicine b. Visiting other laboratories to obtain specialized expertise in areas of laboratory medicine c. Attendance at provincial, national, or international courses, workshops, task forces or committees that promote professional development in laboratory medicine.
2. This grant is not intended to cover examination fees or related expenses
3. The applicant is to submit an online application via the CSCC website for consideration by the Awards Committee. Candidates will submit with their application a statement explaining why this grant is required, and a proposed budget. If their employer provides funds for education and travel, the candidates shall explain why these funds cannot be used for the purpose requested.
4. The deadline for applications is November 30 each year. Preference is to award the grant for an activity occurring in the award year that has not yet occurred. Exceptions may be considered by the Awards Committee with approval by Council.
5. The grant shall usually be presented annually, but, if in the opinion of the Awards Committee, no suitable candidate is available, the grant shall not be made. A maximum of three awards shall be given in any fiscal year. If the grant has not been awarded, the grant may remain open for the remainder of the award year.
6. Recipients of the grant shall receive a maximum of $3000, sponsored by the CSCC Council.  Awarding of this grant is subject to available funds from the CSCC.  Grant amounts may be reduced, or the grant may not be funded in any given year, at the discretion of the Council.
7. The Awards Committee shall choose the recipient(s) of the grant.
8. The Awards Committee shall report its choice(s) to the Council at the Winter Council meeting in the year for which the grant is made.
9. The President of the Society will notify recipient(s) not later than March 1 in the year in which the grant is made.
10. Grant recipients must provide a full accounting of expenses not more than sixty days following completion of the funded activity.
11. The recipient(s) is not usually required to give an address or paper, but the grants will be announced and the awardee(s) recognized at the Annual Meeting of the Society.
12. The amendment of the Terms of Reference is the responsibility of the Council., The terms of reference should be reviewed every five years.

CSCC Grant for Education Application Form

CSCC PROVINCIAL EDUCATION GRANTS TOR

PROVINCIAL EDUCATION GRANTS Purpose

The purpose of Provincial Education Grants is to assist provincial societies with the provision of educational activities for their members. To further this goal, funding is allocated in advance to each provincial section so that they can plan events with the assurance that funds will be available. Funds will only be disbursed following the actual event. Amount of Grant: up to a maximum of $1,000 payable upon receipt of invoices

PROCEDURE

1. Application for the grant is to be made to CSCC Head Office and the Head of the Education and Scientific Affairs Division (ESAD) with supporting documentation of the event in the form of copies of the program and a proposed budget.
2. Request for reimbursement must be received at CSCC Head Office by November 30 of the year in which the event occurred.
3. If a host does not have the ability to fund an event, application for an advance may be made to the Head ESAD. At the discretion of the Head and the Treasurer, funds can be advanced on the understanding that documentation of how the funds were used will be provided after the event takes place.

Approved June 2015

CSCC REGIONAL GRANT APPLICATION FORM